Asia Pacific


27/07/2017 Revenue at June 30, 2017: Satisfactory activity growth

Guerbet is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.


10/07/2017 Guerbet announces plans to streamline its contrast media portfolio

Guerbet announced today that it will phase out sales throughout the world of two products: Hexabrix® (meglumine and sodium ioxaglate) and Optimark® (gadoversetamide).


29/03/2017 Gadolinium-based Contrast Agents: update on PRAC recommendations

Villepinte, March 13, 2017 - Guerbet takes note of the recommendations issued by the Pharmacovigilance Risk Assessment Committee (PRAC), on Gadolinium-based Contrast Agents - procedure under Article 31 of Directive 2001/83/EC.